Elesclomol trials suspended because of safety concerns
Synta Pharmaceuticals and GlaxoSmithKline have announced that they are suspending a phase 3 trial of elesclomol in chemotherapy-naïve patients with stage IV metastatic melanoma because of safety concerns.
Synta Pharmaceuticals and GlaxoSmithKline have announced that they are suspending a phase 3 trial of elesclomol in chemotherapy-naïve patients with stage IV metastatic melanoma because of safety concerns.
The trial (SYMMETRY) compared elesclomol in combination with paclitaxel versus paclitaxel alone. An analysis by an independent data monitoring committee demonstrated that a greater number of deaths occurred among patients treated with combination therapy than among patients treated with paclitaxel alone.
Because of these safety concerns, Synta has announced that other ongoing studies of elesclomol, including a trial of elesclomol plus docetaxel in patients with hormone-refractory metastatic prostate cancer and a dose-escalation trial of elesclomol monotherapy, will also be suspended pending further analysis of the SYMMETRY results.
Elesclomol was granted orphan drug designation in January 2008 and a fast-track designation in November 2006 for the treatment of metastatic melanoma.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
